Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
Sohn
Sang Kyun
SK
Moon
Joon Ho
JH
Cho
Yoon Young
YY
Chae
Yee Soo
YS
Kim
Jong Gwang
JG
Lee
Kun Soo
KS
Hong
Sun Pyo
SP
Kim
Soo Ok
SO
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate